共 82 条
[1]
Rosamond W.(2008)American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 117 e25-e146
[2]
Flegal K.(2008)ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J. 29 2388-2442
[3]
Furie K.(2008)Economic burden of heart failure in the elderly Pharmacoeconomics. 26 447-462
[4]
Dickstein K.(2001)Trends in hospitalization for heart failure in Italy J Cardiovasc Med. 2009;10 367-371
[5]
Cohen-Solal A.(2004)Heart failure clinics have decreased mortality and hospitalisation rates in Sweden Eur Heart J. 25 1368-1369
[6]
Filippatos G.(2009)Understanding the ‘epidemic of heart failure’: a systematic review of trends in determinants of heart failure Eur J Heart Fail 11 472-479
[7]
Liao L.(2001)Economics of chronic heart failure Eur J Heart Fail. 3 283-291
[8]
Allen L.A.(2005)Pharmacological mechanisms contributing to the clinical efficacy of levosimendan Cardiovasc Drug Rev 23 71-98
[9]
Whellan D.J.(2012)Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan Int J Cardiol 159 82-87
[10]
Gigli G.(2012)Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies Crit Care Med 40 634-646